Florent Eymard1, Camille Parsons2, Mark H Edwards2, Florence Petit-Dop3, Jean-Yves Reginster4, Olivier Bruyère4, Xavier Chevalier1, Cyrus Cooper2, Pascal Richette5. 1. Department of rheumatology, Henri-Mondor hospital, AP-HP, 94010 Créteil cedex, France. 2. MRC lifecourse epidemiology unit, Southampton general hospital, Southampton SO16 6YD, UK. 3. Innovative pole of rheumatology, Servier, 92150 Suresnes, France. 4. Department of public health and health economics, university of Liege, 4020 Liege, Belgium. 5. Department of rheumatology, Lariboisière hospital, AP-HP, 75475 Paris cedex 10, France; Inserm U1132, university Paris 7, Lariboisière hospital, AP-HP, 75475 Paris cedex 10, France. Electronic address: pascal.richette@aphp.fr.
Abstract
OBJECTIVE: Epidemiological and experimental studies have suggested that lipid disorders might be involved in the pathophysiology of knee osteoarthritis (OA). Studies assessing the effect of statins on knee OA progression have shown conflicting results. We investigated the impact of statin use on radiological progression in patients with radiological and symptomatic knee OA. METHODS: In total, 336 patients from the placebo arm of SEKOIA trial completed the 3-year follow-up and were included in this post-hoc analysis. Statin use was recorded at baseline interview. Minimal medial tibiofemoral joint space was measured on plain radiographs by an automated method at baseline and then annually. Radiologic progression was defined as joint space narrowing≥0.5mm over 3 years. RESULTS: Overall, 71 patients were statin users (21.1%). They had a higher BMI (31.1±5.3 vs. 29.3±5.2kg/m2, P=0.008), a higher sum of metabolic factors (≥3 factors: 43.7% vs 7.2%; P for trend<0.001) and a higher rate of radiological progression (49.3% vs. 32.1%, P=0.007) as compared to statin non-users. The significant association between radiological progression and statin use was independent of age, gender, WOMAC global score, disease duration, baseline joint space width, hypertension, type 2 diabetes, obesity (BMI>30kg/m2) and cardiovascular diseases [relative risk 1.49 (95% CI: 1.10-2.02), P=0.010]. CONCLUSION: Among patients with knee OA, statin use was associated with radiological worsening over 3 years, regardless of other potential confounding factors (obesity, type 2 diabetes, hypertension, disease duration, symptom intensity and radiological severity).
OBJECTIVE: Epidemiological and experimental studies have suggested that lipid disorders might be involved in the pathophysiology of knee osteoarthritis (OA). Studies assessing the effect of statins on knee OA progression have shown conflicting results. We investigated the impact of statin use on radiological progression in patients with radiological and symptomatic knee OA. METHODS: In total, 336 patients from the placebo arm of SEKOIA trial completed the 3-year follow-up and were included in this post-hoc analysis. Statin use was recorded at baseline interview. Minimal medial tibiofemoral joint space was measured on plain radiographs by an automated method at baseline and then annually. Radiologic progression was defined as joint space narrowing≥0.5mm over 3 years. RESULTS: Overall, 71 patients were statin users (21.1%). They had a higher BMI (31.1±5.3 vs. 29.3±5.2kg/m2, P=0.008), a higher sum of metabolic factors (≥3 factors: 43.7% vs 7.2%; P for trend<0.001) and a higher rate of radiological progression (49.3% vs. 32.1%, P=0.007) as compared to statin non-users. The significant association between radiological progression and statin use was independent of age, gender, WOMAC global score, disease duration, baseline joint space width, hypertension, type 2 diabetes, obesity (BMI>30kg/m2) and cardiovascular diseases [relative risk 1.49 (95% CI: 1.10-2.02), P=0.010]. CONCLUSION: Among patients with knee OA, statin use was associated with radiological worsening over 3 years, regardless of other potential confounding factors (obesity, type 2 diabetes, hypertension, disease duration, symptom intensity and radiological severity).
Authors: Francis Guillemin; Anne-Christine Rat; Christian H Roux; Bruno Fautrel; Bernard Mazieres; Xavier Chevalier; Liana Euller-Ziegler; Patrice Fardellone; Evelyne Verrouil; Johanne Morvan; Jacques Pouchot; Joel Coste; Alain Saraux Journal: Joint Bone Spine Date: 2012-06-20 Impact factor: 4.929
Authors: Klaus W Frommer; Andreas Schäffler; Stefan Rehart; Angela Lehr; Ulf Müller-Ladner; Elena Neumann Journal: Ann Rheum Dis Date: 2013-11-27 Impact factor: 19.103
Authors: I-E Triantaphyllidou; E Kalyvioti; E Karavia; I Lilis; K E Kypreos; D J Papachristou Journal: Osteoarthritis Cartilage Date: 2012-11-11 Impact factor: 6.576
Authors: G Engström; M Gerhardsson de Verdier; J Rollof; P M Nilsson; L S Lohmander Journal: Osteoarthritis Cartilage Date: 2008-08-29 Impact factor: 6.576
Authors: D T Felson; R C Lawrence; P A Dieppe; R Hirsch; C G Helmick; J M Jordan; R S Kington; N E Lane; M C Nevitt; Y Zhang; M Sowers; T McAlindon; T D Spector; A R Poole; S Z Yanovski; G Ateshian; L Sharma; J A Buckwalter; K D Brandt; J F Fries Journal: Ann Intern Med Date: 2000-10-17 Impact factor: 25.391
Authors: Aqeel M Alenazi; Sakher M Obaidat; Mohammed M Alshehri; Shaima Alothman; Corey Gray; Jason Rucker; Lemuel R Waitman; Patricia M Kluding Journal: Pain Med Date: 2020-05-01 Impact factor: 3.750
Authors: Bahram Mohajer; Ali Guermazi; Philip G Conaghan; Francis Berenbaum; Frank W Roemer; Arya Haj-Mirzaian; Clifton O Bingham; Kamyar Moradi; Xu Cao; Mei Wan; Shadpour Demehri Journal: Eur Radiol Date: 2022-01-19 Impact factor: 7.034
Authors: Aqeel M Alenazi; Bader A Alqahtani; Vishal Vennu; Mohammed M Alshehri; Ahmad D Alanazi; Saud M Alrawaili; Kamlesh Khunti; Neil A Segal; Saad M Bindawas Journal: Int J Environ Res Public Health Date: 2021-04-21 Impact factor: 3.390